ClinicalTrials.gg
RecruitingNCT05597202DOTAFLAMEUpdated May 9, 2023

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

A Phase 4 interventional study of Semaglutide, 2.0 mg/mL in Type 2 Diabetes, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 4, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Planned enrollment
149th of 163
22 · median 104
Started
2023
with 19 others
Phase 4
40 of 163
17 open now
Primary completion
2024-03
later than 1 of 44 live
Registered
108th of 163
by date
Lead sponsor
1 of 163
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 149th largest by planned enrollment, is one of 20 that started in 2023, is one of 40 in phase 4, reaches primary completion later than 1 of the 44 other live ones, and was the 108th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic stem cell composition in vivo, and whether these changes can be reversed with glucagon like peptide 1 receptor (GLP1R)-agonism.

Read the detailed description

We will use 68Ga-Dotatate PET/CT scans, bone marrow aspirations and peripheral blood analyses to determine the effect of type 2 diabetes on vascular wall inflammation, and hematopoietic stem cell composition, and whether these changes can be reversed using high dose semaglutide treatment, up to 2.0mg subcutaneously per week, for a period of six months.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • diabetes mellitus
  • dotatate
  • bone marrow
  • semaglutide
  • vascular inflammation
  • glp1
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >50 years old
  • Diagnosed with type 2 diabetes
  • >64mmol/mol

Exclusion criteria

Exclusion Criteria:

  1. (History of) malignant diseases or any medical condition that could interfere with the conduct of the study in the opinion of the investigator.
  2. Chronic or recent infections and/or clinical signs of infection and/or a plasma C-reactive protein above 10ng/ml
  3. Auto-immune diseases (including type 1 diabetes)
  4. Recent or chronic or antibiotic usage
  5. Use of any GLP1R-agonist at baseline or prior intolerance to use of GLP1R-agonists.
  6. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
  7. Uncontrolled hypertension (systolic blood pressure > 180mmHg, diastolic blood pressure > 100mmHg)
  8. Uncontrolled chronic inflammatory conditions, including gout.
  9. Women of childbearing age who are not using effective .
  10. Heart failure (NYHA) class IV at screening visit.
  11. Active liver disease or hepatic dysfunction, defined as (ASAT) or alanine aminotransferase (ALAT) ≥ 2 times the (ULN) at screening visit.
  12. Pancreatitis in medical history.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Treatment arm

    Will receive semaglutide treatment for 6 months, at the highest tolerable dose, up to a maximum of 2.0mg weekly.

    Drug: Semaglutide, 2.0 mg/mL

Interventions

  • DrugSemaglutide, 2.0 mg/mL

    Drug page: SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.

06

What researchers measure

Primary outcomes

  1. Difference in coronary 68Ga-Dotatate uptake after treatment.

    The within subject comparison of 68Ga-Dotatate uptake in the coronary arteries before and after semaglutide treatment, expressed as a difference in TBRmax.

    Time frame: 6 months

Secondary outcomes

  1. Difference in bone marrow aspirates after treatment.

    The within subject comparison of bone marrow aspirates before and after semaglutide treatment, expressed as a difference in stem cell count.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • AMC
    Amsterdam, Noord-Holland 1105AZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Mar 2024, 14 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 14 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 27, 2022
StartActual
Jan 1, 2023
Primary completionEst.
Mar 2024
CompletionEst.
Apr 2024
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05597202
Collaborators
Dutch Heart Foundation
Responsible party
Nordin Hanssen (Principal investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Oct 27, 2022
Start date
Jan 1, 2023
Primary completion
Mar 2024 (estimated)
Completion
Apr 2024 (estimated)
Last update
May 9, 2023

Study contacts

R.F. Oostveen, MD
Contact
r.oostveen@amsterdamumc.nl
020 5667050

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion